These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25242254)

  • 1. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
    Xu HR; Fu L; Zhan P; Liu XY
    SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
    Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
    Vanangamudi M; Poongavanam V; Namasivayam V
    Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
    Babu S; Sohn H; Madhavan T
    Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
    de Brito MA; Rodrigues CR; Cirino JJ; de Alencastro RB; Castro HC; Albuquerque MG
    J Chem Inf Model; 2008 Aug; 48(8):1706-15. PubMed ID: 18671385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
    Murugesan V; Prabhakar YS; Katti SB
    J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
    Sivan SK; Manga V
    J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Hu R; Barbault F; Delamar M; Zhang R
    Bioorg Med Chem; 2009 Mar; 17(6):2400-9. PubMed ID: 19250835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents.
    Shagufta ; Kumar A; Panda G; Siddiqi MI
    J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach.
    Ravichandran V; Prashantha Kumar BR; Sankar S; Agrawal RK
    Eur J Med Chem; 2009 Mar; 44(3):1180-7. PubMed ID: 18687505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
    Mao Y; Li Y; Hao M; Zhang S; Ai C
    J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
    Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
    Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
    Zhou Z; Madura JD
    J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.
    Cichero E; Cesarini S; Fossa P; Spallarossa A; Mosti L
    Eur J Med Chem; 2009 May; 44(5):2059-70. PubMed ID: 19046616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
    San Juan AA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
    Gaurav A; Singh R
    Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.